Bispecific antibodies used in the bridging period include CD20/CD3-targeting mosunetuzumab and glofitamab for B-NHL and CD19/CD3-targeting blinatumomab for B-ALL (160, 164). Here, CD19 is linked to acute lymphoblastic leukemia.